{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:30:27Z","timestamp":1794047427382,"version":"4.8.0"},"reference-count":25,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"6","license":[{"start":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T00:00:00Z","timestamp":1669248000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Mantle cell lymphoma (MCL) is an incurable B-cell non-Hodgkin lymphoma characterized by frequent relapses. The development of resistance to ibrutinib therapy remains a major challenge in MCL. We previously showed that glutaminolysis is associated with resistance to ibrutinib. In this study, we confirmed that glutaminase (GLS), the first enzyme in glutaminolysis, is overexpressed in ibrutinib-resistant MCL cells, and that its expression correlates well with elevated glutamine dependency and glutaminolysis. Furthermore, we discovered that GLS expression correlates with MYC expression and the functioning of the glutamine transporter ASCT2. Depletion of glutamine or GLS significantly reduced cell growth, while GLS overexpression enhanced glutamine dependency and ibrutinib resistance. Consistent with this, GLS inhibition by its specific inhibitor telaglenastat suppressed MCL cell growth both in vitro and in vivo. Moreover, telaglenastat showed anti-MCL synergy when combined with ibrutinib or venetoclax in vitro, which was confirmed using an MCL patient-derived xenograft model. Our study provides the first evidence that targeting GLS with telaglenastat, alone or in combination with ibrutinib or venetoclax, is a promising strategy to overcome ibrutinib resistance in MCL.<\/jats:p>","DOI":"10.3324\/haematol.2022.281538","type":"journal-article","created":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T14:15:50Z","timestamp":1669299350000},"page":"1616-1627","source":"Crossref","is-referenced-by-count":17,"title":["Targeting glutaminase is therapeutically effective in ibrutinib-resistant mantle cell lymphoma"],"prefix":"10.3324","volume":"108","author":[{"given":"Lingzhi","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexa","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingsong","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxuan","family":"Che","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jovanny","family":"Vargas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Leeming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixin","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian Changying","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2022,11,24]]},"reference":[{"key":"48566","doi-asserted-by":"crossref","unstructured":"Jain P, Dreyling M, Seymour JF, Wang M. High-risk mantle cell lymphoma: definition, current challenges, and management. J Clin Oncol. 2020; 38(36):4302-4316.","DOI":"10.1200\/JCO.20.02287"},{"key":"48567","doi-asserted-by":"crossref","unstructured":"Wang ML, Rule S, Martin P. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013; 369(6):507-516.","DOI":"10.1056\/NEJMoa1306220"},{"key":"48568","doi-asserted-by":"crossref","unstructured":"Zhang L, Yao Y, Zhang S. Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma. Sci Transl Med. 2019; 11(491):eaau1167.","DOI":"10.1126\/scitranslmed.aau1167"},{"key":"48569","doi-asserted-by":"crossref","unstructured":"Duraj T, Carrion-Navarro J, Seyfried TN, Garcia-Romero N, Ayuso-Sacido A. Metabolic therapy and bioenergetic analysis: the missing piece of the puzzle. Mol Metab. 2021; 54:101389.","DOI":"10.1016\/j.molmet.2021.101389"},{"key":"48570","doi-asserted-by":"crossref","unstructured":"Samudio I, Fiegl M, Andreeff M. Mitochondrial uncoupling and the Warburg effect: molecular basis for the reprogramming of cancer cell metabolism. Cancer Res. 2009; 69(6):2163-2166.","DOI":"10.1158\/0008-5472.CAN-08-3722"},{"key":"48571","doi-asserted-by":"crossref","unstructured":"Bolzoni M, Chiu M, Accardi F. Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target. Blood. 2016; 128(5):667-679.","DOI":"10.1182\/blood-2016-01-690743"},{"key":"48572","doi-asserted-by":"crossref","unstructured":"Patel D, Menon D, Bernfeld E. Aspartate rescues S-phase arrest caused by suppression of glutamine utilization in KRas-driven cancer cells. J Biol Chem. 2016; 291(17):9322-9329.","DOI":"10.1074\/jbc.M115.710145"},{"key":"48573","doi-asserted-by":"crossref","unstructured":"M\u00e1rquez J, Campos-Sandoval JA, Pe\u00f1alver A. Glutamate and brain glutaminases in drug addiction. Neurochem Res. 2017; 42(3):846-857.","DOI":"10.1007\/s11064-016-2137-0"},{"key":"48574","doi-asserted-by":"crossref","unstructured":"Guo H, Zeng D, Zhang H. Dual inhibition of PI3K signaling and histone deacetylation halts proliferation and induces lethality in mantle cell lymphoma. Oncogene. 2019; 38(11):1802-1814.","DOI":"10.1038\/s41388-018-0550-3"},{"key":"48575","doi-asserted-by":"crossref","unstructured":"Li CJ, Jiang C, Liu Y. Pleiotropic action of novel Bruton's tyrosine kinase inhibitor BGB-3111 in mantle cell lymphoma. Mol Cancer Ther. 2019; 18(2):267-277.","DOI":"10.1158\/1535-7163.MCT-18-0478"},{"key":"48576","doi-asserted-by":"crossref","unstructured":"Zhang S, Jiang VC, Han G. Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evolution in refractory mantle cell lymphoma. Nat Commun. 2021; 12(1):2877.","DOI":"10.1038\/s41467-021-22872-z"},{"key":"48577","doi-asserted-by":"crossref","unstructured":"Jiang C, Zhu Y, Zhou Z. TMEM43\/LUMA is a key signaling component mediating EGFR-induced NF-kappaB activation and tumor progression. Oncogene. 2017; 36(20):2813-2823.","DOI":"10.1038\/onc.2016.430"},{"key":"48578","doi-asserted-by":"crossref","unstructured":"Dobin A, Davis CA, Schlesinger F. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013; 29(1):15-21.","DOI":"10.1093\/bioinformatics\/bts635"},{"key":"48579","doi-asserted-by":"crossref","unstructured":"Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014; 15(12):550.","DOI":"10.1186\/s13059-014-0550-8"},{"key":"48580","doi-asserted-by":"crossref","unstructured":"Subramanian A, Tamayo P, Mootha VK. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102(43):15545-15550.","DOI":"10.1073\/pnas.0506580102"},{"key":"48581","doi-asserted-by":"crossref","unstructured":"Liberzon A, Birger C, Thorvaldsdottir H, Ghandi M, Mesirov JP, Tamayo P. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 2015; 1(6):417-425.","DOI":"10.1016\/j.cels.2015.12.004"},{"key":"48582","unstructured":"Li JCA. Modeling survival data: extending the Cox model. Sociol Method Res. 2003; 32(1):117-120."},{"key":"48583","doi-asserted-by":"crossref","unstructured":"Ren P, Yue M, Xiao D. ATF4 and N-Myc coordinate glutamine metabolism in MYCN-amplified neuroblastoma cells through ASCT2 activation. J Pathol. 2015; 235(1):90-100.","DOI":"10.1002\/path.4429"},{"key":"48584","doi-asserted-by":"crossref","unstructured":"Gao P, Tchernyshyov I, Chang TC. c-Myc suppression of miR-23a\/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature. 2009; 458(7239):762-765.","DOI":"10.1038\/nature07823"},{"key":"48585","doi-asserted-by":"crossref","unstructured":"Vasan K, Clutter M, Dunne SF. Genes involved in maintaining mitochondrial membrane potential upon electron transport chain disruption. Front Cell Dev Biol. 2022; 10:781558.","DOI":"10.3389\/fcell.2022.781558"},{"key":"48586","doi-asserted-by":"crossref","unstructured":"Friday E, Oliver R, Welbourne T, Turturro F. Glutaminolysis and glycolysis regulation by troglitazone in breast cancer cells: relationship to mitochondrial membrane potential. J Cell Physiol. 2011; 226(2):511-519.","DOI":"10.1002\/jcp.22360"},{"key":"48587","doi-asserted-by":"crossref","unstructured":"Lee P, Malik D, Perkons N. Targeting glutamine metabolism slows soft tissue sarcoma growth. Nat Commun. 2020; 11(1):498.","DOI":"10.1038\/s41467-020-14374-1"},{"key":"48588","doi-asserted-by":"crossref","unstructured":"Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest. 2000; 105(8):1045-1047.","DOI":"10.1172\/JCI9872"},{"key":"48589","doi-asserted-by":"crossref","unstructured":"Yang L, Venneti S, Nagrath D. Glutaminolysis: a hallmark of cancer metabolism. Annu Rev Biomed Eng. 2017; 19:163-194.","DOI":"10.1146\/annurev-bioeng-071516-044546"},{"key":"48590","doi-asserted-by":"crossref","unstructured":"Jacque N, Ronchetti AM, Larrue C. Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition. Blood. 2015; 126(11):1346-1356.","DOI":"10.1182\/blood-2015-01-621870"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2022.281538\/75070","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2022.281538\/75663","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/10879\/75070","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:02:50Z","timestamp":1794045770000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2022.281538"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,24]]},"references-count":25,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,6,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2022.281538","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11,24]]}}}